Subscribe to Ear/Nose/Throat
View Sample

FREE Email Newsletter

Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia

June 3, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

CHICAGO, June 3, 2011 /- Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML). Data will be presented at the...

Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs)

June 2, 2011 1:33 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, June 2, 2011 /- Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3-7. The poster presentation is based on...

At SIIM 2011 Siemens Showcases Imaging IT Solutions for Driving Greater Value in Radiology and Other Specialties

June 2, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, June 2, 2011 /- Siemens Healthcare (NYSE: SI) will showcase its portfolio of imaging information technology (IT) and workflow management solutions at the Society for Imaging Informatics in Medicine (SIIM) 2011 Annual Meeting from June 2-5, 2011, (booth 825) in the Gaylord...


CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment

May 31, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

KING OF PRUSSIA, Pa., May 31, 2011 /- CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat...

Brin Wojcicki Foundation Announces $50-Million Challenge Grant to Michael J. Fox Foundation to Spur Progress Toward Parkinson's Cure

May 31, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 31, 2011 /PRNewswire-USNewswire/ --Sergey Brin and Anne Wojcicki announced a $50-million challenge spurring existing and new donors at every level to give, or increase giving, to The Michael J. Fox Foundation for Parkinson's Research (MJFF). The Challenge is now in effect...

Bayer's Discrimination Lawsuit Now Requires Extra-Strength Cure

May 25, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

NEWARK, N.J., May 25, 2011 /- Just days after the one year anniversary of winning a $250 million verdict for female sales representatives at Novartis Pharmaceuticals Corporation, the law firm of Sanford Wittels & Heisler LLP filed a nearly identical class action on behalf of female...

XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System

May 25, 2011 4:33 am | by Bio-Medicine.Org | News | Comments

ATLANTA, May 25, 2011 /- XDATA retains Adapt IP Ventures to market XDATA's intellectual property including patents and fully-functioning prototype focused on breast cancer detection. Over many decades, XDATA has developed, patented and tested methods and devices for automatically...

An X Prize for Mobile Diagnostics

May 22, 2011 8:35 pm | by Massachusetts Institute of Technology | News | Comments

A $10 million prize would go to the first device that can diagnose a range of diseases with the same accuracy as a team of doctors.


Red Hill Studios/UCSF Partnership to Showcase 'Gaming Therapy' for People With Parkinson's Disease at Games for Health Conference

May 16, 2011 12:34 pm | by Bio-Medicine.Org | News | Comments

BOSTON, May 16, 2011 /- Red Hill Studios, in partnership with the UCSF School of Nursing, will showcase a custom suite of Kinect™-based physical therapy games that have been specifically designed to help people with Parkinson's slow the progression of this neurodegenerative disease....

AlphaDetail AlphaPulseâ„¢: Anticipated Impact of CATT Trial in Wet AMD Treatment

May 16, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

SAN MATEO, Calif., May 16, 2011 /- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT). AlphaDetail, Inc., a leader in global ophthalmology primary...

Simpler Genome Sequencing

May 13, 2011 2:35 pm | by Massachusetts Institute of Technology | News | Comments

A startup hopes to make the technology cheap enough that it's feasible for a typical hospital lab.

FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors

May 6, 2011 6:42 am | by Bio-Medicine.Org | News | Comments

MANHATTAN BEACH, Calif., May 6, 2011 /- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.  Neuroendocrine tumors make up less than five percent of all...

Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET

May 5, 2011 5:35 pm | by Bio-Medicine.Org | News | Comments

EAST HANOVER, N.J., May 5, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients...


New CE Marked Test Simultaneously Detects Up To 95% of Gastrointestinal Infections in Under Five Hours

May 4, 2011 10:40 pm | by Bio-Medicine.Org | News | Comments

AUSTIN, Texas and MILAN, May 5, 2011 /- Luminex Corporation (NASDAQ: LMNX ) announced today that it has received CE marking for its new xTAG Gastrointestinal Pathogen Panel (GPP).This innovative assay is the first test of its kind to help identify up to 95 percent of the disease causing...

Immunetics lands $2.4M NIH grant for parasite detection

May 3, 2011 7:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Infectious disease testing company Immunetics Inc. has won a three-year, $2.4 million Phase 2 SBIR grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

IRIDEX Announces First Quarter 2011 Conference Call and Release Date

April 28, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., April 28, 2011 /- IRIDEX Corporation (NASDAQ: IRIX ) today announced that it will release its first quarter 2011 financial results after the market closes on Thursday, May 5, 2011.  In conjunction with the release, the Company will host a conference call with...

Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop

April 28, 2011 6:37 am | by Bio-Medicine.Org | News | Comments

SOUTH SAN FRANCISCO, Calif., April 28, 2011 /- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in...

Sacramento Police Upgrades Search and Rescue Technology with EmSeeQ® Wearable Locator System to Improve Safety for At-Risk Adults and Children

April 27, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

FRISCO, Texas, April 27, 2011 /- The City of Sacramento Police Department (Calif.) is proud to announce today the availability of the EmFinder's EmSeeQ® wearable locator system that uses cellular technology to quickly locate individuals who are prone to wandering due to cognitive...

Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy

April 26, 2011 5:36 pm | by Bio-Medicine.Org | News | Comments

BOCA RATON, Fla., April 26, 2011 /- The Premier healthcare alliance, a network of more than 2,500 U.S. hospitals and 73,000-plus other healthcare sites working together to achieve high quality, cost-effective care, has awarded Sensus Healthcare, Inc. , the leading provider of FDA-approved...

Sanare and BrightSky Announce National Strategic Partnership with American Diabetes Association

April 21, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

RENO, Nev., April 21, 2011 /- Sanare, LLC, a leading provider of care management solutions for people with diabetes, and its new consumer brand, BrightSky, have become National Strategic Partners of the American Diabetes Association.® (Logo:...

Daughter of Journalist Robert MacNeil States that Son Regressed Into Autism After Vaccines

April 19, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

ATLANTA, April 19, 2011 /PRNewswire-USNewswire/ -- Alison MacNeil issued the following statements today regarding vaccines. MacNeil's family Autism story is running on PBS this week: "When I vaccinated my son Nick, I did not know vaccine manufacturers are not required to test the safety...

FDA Approves New Medical Device for Form of Brain Cancer

April 15, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., April 15, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration recently approved the NovoTTF-100A System, a new device to treat adults with glioblastoma multiforme (GBM) that recurs or progresses after receiving chemotherapy and radiation therapy....

Merz Pharmaceuticals Joins Patient Advocates to Raise Awareness of Cervical Dystonia and Blepharospasm

April 14, 2011 6:37 am | by Bio-Medicine.Org | News | Comments

GREENSBORO, N.C., April 14, 2011 /- Merz Pharmaceuticals, LLC, maker of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign. With the help of patient advocates, "Make Your Mark" celebrates...

New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment

April 14, 2011 4:35 am | by Bio-Medicine.Org | News | Comments

BRUSSELS, April 14, 2011 /- New 5-year data from the longest prospective open-label Restless Legs Syndrome (RLS) study to date, show that Neupro® (rotigotine) demonstrated continued symptomatic clinical benefit with a low risk of augmentation. Over the five year period, clinically...

Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study

April 12, 2011 8:37 am | by Bio-Medicine.Org | News | Comments

RESEARCH TRIANGLE PARK, N.C., April 12, 2011 /- Max Neeman meets enrollment and timeline of 15,000 for a large, Phase IV metabolic disorder trial across 1200 sites throughout India. As a leading Indian CRO, the company has completed multiple Phase IV studies for global sponsors with...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.